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VOLUME , NUMBER , JUNE Letter to the EditorDear Dr. Walson:
Vlase et al1 recently reported on the pharmacokinetic analysis of an interaction
between fluoxetine and omeprazole. I wanted to offer a comment and correction of an
error that is commonly made in the medical literature. The intention of this
commentary is to offer a clarification of a useful concept and is not intended to single
out those authors nor to detract in any way from the Vlase et al1 study, which is a
useful addition to the literature.
One of the pharmacokinetic parameters reported was “mean residence time,” or
MRT. It is important to understand conceptually that MRT is defined as the average
amount of time that drug molecules spend in the body after having gained access to
the body (ie, the systemic circulation). While MRT is independent of the route of
administration, its calculation is not. This was made clear in earlier papers by Perrier
and Mayersohn2 and Karol.3
It is quite common to read in the literature that MRT was calculated as the ratio
f the area under the first moment curve (AUMC) to the area under the plasma
oncentration–time curve (AUC), which is then referred to as being the definition of
RT. This is not the definition of MRT and, as given, it is only a correct calculation
following an intravenous bolus dose of drug. Under all other circumstances of drug
dosing (ie, routes of administration), that ratio will overestimate the correct MRT,
since the calculation incorporates the absorption or input process. Thus, following
oral administration,
AUMC
AUC
MRTMAT
the ratio of AUMC/AUC is the sum of MRT and the mean absorption (or input) time
(MAT). The latter may be estimated, assuming first-order absorption, as the recip-
rocal of the absorption rate constant (ka).
The absorption rate constant can be estimated by iterating the value for Tmax;
hile not a particularly accurate or robust estimate, it was done as an exercise for this
ommentary. The estimated value for the ka of omeprazole for both the control and
xperiment was approximately 0.8 h–1, giving a value for MAT of about 1.25 h.
ubtracting that value from the “MRT” values reported by Vlase et al1 in Table I
gives values for a “corrected MRT” of 1.08 and 2.10 h for the control and experiment,
respectively. Since the half-life for omeprazole varies in the population from about 0.5
to 1.0 h, taking the midpoint of that range, 0.75 h (K 0.92 h-1), allows calculation
of an MRT of about 1.08 h, assuming a one-compartment model (MRT  1/K). The
latter value is identical to the one calculated above for a “corrected MRT”. The longer
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M. Mayersohn“MRT” reported from the combination of omeprazole and fluoxetine is consistent
with the increase in half-life, although the “corrected MRT” value is probably not
accurate.
I suspect that this calculation of “MRT,” as the ratio of AUMC/AUC, is simply one
of many calculations and metrics obtained from the analysis of plasma concentration–
time data sets with application of noncompartmental methods using an established
computer program. It is this routine use of computer programs that I believe has led
to the general misapplication and incorrect interpretation of residence times. Inves-
tigators need to be cognizant of the correct definition of the pharmacokinetic metrics
that are calculated.
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